IMMUNOLOGY PUBLICATIONS

  1. Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H and Daniel GW. Characterizing vaccine-associated risks using cubic smoothing splines. American Journal of Epidemiology 2012;176(10):949-57.
  2. Phung OJ. Focus on belimumab: a B-lymphocyte stimulator inhibitor for systemic lupus erythematosus. Formulary 2011;46:118,127-129.
  3. Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J and Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunology Letters 2010;131(2):126-130.
  4. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE and Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 2010;116(2):369-376.
  5. Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J and Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Current Pharmaceutical Design 2010;16(3):268-276.
  6. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J and Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology 2010;28(24):3880-9.
  7. Phung OJ and Coleman CI. Focus on golimumab: a human anti-TNF monoclonal antibody for the treatment of autoimmune joint diseases. Formulary 2009;44:264-273.
  8. Villagra A, Wang H, Cheng F, Maurin M, Suarez I, Nguyen D, Wright KL, Atadja AP, Bhalla K, Pinilla-Ibarz J, Seto E and Sotomayor EM. A novel role of histone deacetylase 11 (HDAC11) as transcriptional regulator of IL-10 and immuno tolerance. Nature Immunology 2009;10(1):92-100.
  9. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS and Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leukemia Research 2006;30(10):1293-8.
  10. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F and Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leukemia Research 2008;32(6):936-43.
  11. Kappel BJ, Pinilla-Ibarz J, Eng J, van der Brink and Scheinberg D. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood 2006;107(5):2045-51.
  12. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F and Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106(7):1569-80.
  13. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A and Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4079-88.
  14. Pinilla-Ibarz J, Korontsvit T, Roberts W, Cathcart K and Scheinberg DA. Synthetic analogue peptides derived from the bcr/abl fusion protein induce heteroclitic T cell responses. Haematologica 2005;90:1324-32.
  15. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H and Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4070-8.
  16. Tran K and Hadjiconstantinou M. Immunomodulatory effects of methamphetamine on astrocytes. Journal of Neurovirology 2004;10(Suppl 3):85.
  17. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S and Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-9.
  18. Roberts W, Agus D, Pinilla-Ibarz J, Zelenetz A, Livingston P and Scheinberg D. Vaccination with CD20 peptide conjugate induce a biologically active, immune response in mice. Blood 2002;99:3748-55.
  19. Wasowska B, Qian Z, Cangello D, Behrens E, Tran K, Layton J, Sanfilippo F and Baldwin W. Passive transfer of alloantibodies restores acute cardiac rejection in Ig KO mice. Transplantation 2001;71(6):727-33.
  20. Jurcic J, Cathcart K, Pinilla-Ibarz J and Scheinberg DA. Immunotherapy of leukemias. Current Opinion in Hematology 2000;7(4):247-54.
  21. Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Reviews 2000;14:11-120.
  22. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J and Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781-7.
  23. Cathcart K, Pinilla-Ibarz J and Scheinberg DA. Immunotherapeutics strategies in CML. In: Carella et al., ed. Chronic Myeloid Leukemia: Biology and Treatment. London: Martin Dunitz Publishers; 2001:507-19.